T +41 (0)44 387 28 00 | info@orl-zentrum.com

Prof. Dr. med. Gerhard Huber

Facharzt FMH für
speziell: Hals- und Gesichtschirurgie


Deutsch, Englisch, Französisch, Italienisch


  • Operative Behandlung von Tumoren des Kopf-Halsbereiches
  • Operative Behandlung von Schilddrüsen und Nebenschilddrüsenerkrankungen
  • Operative Behandlung von Speicheldrüsenerkrankungen
  • Laserchirurgische Behandlung von Kehlkopf- und Rachenerkrankungen


seit 2021

Praxistätigkeit, ORL-Zentrum, Hirslanden Klinik, Zürich

2018 – 21         

Kantonsspital St. Gallen, (Prof. S. Stöckli), Leitender Arzt Bereiche Kopf-Halschirurgie

2012 – 17 

Universitätsspital Zürich, (Prof. R. Probst, Prof. A. Huber), Abteilungsleiter, leitender  Arzt, Leiter Kopf-Hals-Tumorzentrum USZ, Privatdozent (PD); Mitglied der medizinischen Fakultät der Universität Zürich

2008 – 12

Universitätsspital Zürich, Leitender Arzt a.i., Kopf-Hals-Chirurgie


Universitätsspital Zürich, Oberarzt

2006 – 07   

Kantonsspital Aarau, (Prof. M. Podvinec), Oberarzt

2004 – 06 

University Hospital of Calgary, Alberta, Kanada, (Prof. J. Dort, Prof. W. Matthews, Prof. W. Temple), Fellowship in Surgical Oncology/Head and Neck Surgery

2002 – 04 

UniversitätsSpital Basel, (Prof. R. Probst), Assistenzarzt Hals-Nasen-Ohrenklinik,

2000 – 02

Kantonsspital Aarau, (Prof. M. Podvinec), Assistenzarzt Hals-Nasen-Ohrenklinik 

1999 – 2000

Kantonsspital Aarau, (Prof. R. Schlumpf), Assistenzarzt  Chirurgie

1997 – 98  

Universität Zürich, (PD Dr. F. Salomon), Dozent für Humanphysiologie und medizinische, Terminologie / Schule für Ernährungsberatung 

1996 – 99

UniversitätsSpital Zürich, Institut für Neuropathologie (Prof. A. Aguzzi), Assistenzarzt, Forschung und diagnostische Tätigkeit; mehrere Projekte in der Prionenforschung 


English skills assessment, USMLE Step I & II  

1990 – 96 

Studium der Humanmedizin and der Universität Zürich, Staatsexamen November 1996 (5.64)  


English training at University of Santa Barbara (UCSB)  

1982 – 89 

Gymnasium Stiftsschule Einsiedeln/SZ 

Berufliche Meilensteine


Titularprofessur der Universität Zürich

2014 – 15   

Seminar für integratives Spitalmanagement, Universität St. Gallen  


«Venia legendi», Privatdozent, Universität Zürich  


Examen für Kopf-Halschirurgie (Subtitel FMH)  


Facharztexamen in HNO-Heilkunde FMH  

1997 – 99  

Post-graduate course in experimental medicine and biology (Swiss national fund); MSc  


Dissertation: «The role of the gut associated lymphatic tissue (GALT) and marcophages in transport of Prions into the CNS»

  1. Impact of the new TNM-Staging System (8th edition) on oral tongue cancers. Ammann Y, Beutner U , Vital DG, Morand GB, Broglie Daeppen MA, Born D, Stoeckli SJ, Huber GF, 2021 Swiss Med Wkly. Feb 21;145
  2. Evaluation of 18F-FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and heck squamous cell carcinoma. de Galiza PBarbosa F , Riesterer O, Tanadini-Lang S, Stieb S, Studer S, Pruschy M, Huber GF, Huellner MW, Stolzmann P, Veit-Haibach: Head Neck 2020 Feb;42(2):163-170.
  3. First clinico-pathological evidence of a non PSMA-related uptake mechanism for 68Ga-PSMA-11 in salivary glands. Rupp NJ, Umbricht CA, Pizzuto DA, Lenggenhager D, Töpfer A, Müller J, Mühlematter UJ, Ferraro DA, Messerli M, Morand GB, Huber GF, Eberli D, Schibli R, Schibli R, Burger IA. J Nucl Med. 2019 Feb 8
  4. Long-term speech and swallowing function after primary resection and sentinel node biopsy for early oral squamous cell carcinoma. Romer CAE, Broglie Daeppen MA, Mueller M, Huber GF, Guesewell S, Stoeckli SJ. Oral Oncol. 2019 Feb;89:127-132
  5. Comparison of contemporary staging systems for oropharynx cancer in a surgically treated multi-institutional cohort. Elicin O, Broglie MA, Fankhauser N, Stoeckli SJ, Pasche P, Reinhard A, Bongiovanni M, Huber GF, Morand GB, Soltermann A, Arnold A, Dettmer MS, Arnoux A, Stauffer E, Espeli V, Martucci F, Aebersold DM, Giger R. Head Neck. 2018 Dec 28.
  6. Morand GB, Ikenberg K, Vital DG, Cardona I, Moch H, Stoeckli SJ, Huber GF (2018) Preoperative assessment of CD44-mediated depth of invasion as predictor of occult metastases in early oral squamous cell carcinoma. Head Neck. Dec 18. doi: 10.1002/hed.25532. [Epub ahead of print]
  7. Use of MRI and FDG-PET/CT to predict fixation of advanced hypopharyngeal squamous cell carcinoma to prevertebral space. Meerwein CM, Pizzuto DA, Vital D, Morand GB, Stolzmann P, Huber GF, Huellner MW (2018) Head Neck. Dec 18. doi: 10.1002/hed.25431. [Epub ahead of print]
  8. Sentinel lymph node biopsy for early stage tongue cancer-a 14-year single-centre experience.Hingsammer L, Seier T, Zweifel D, Huber G, Rücker M, Bredell M, Lanzer M. Int J Oral Maxillofac Surg. 2018 Oct 30. pii: S0901-5027(18)30420-X. doi: 10.1016/j.ijom.2018.10.011. [Epub ahead of print]
  9. Comparison of PI3K Pathway in HPV-Associated Oropharyngeal Cancer With and Without Tobacco Exposure. Kiessling SY, Broglie MA, Soltermann A, Huber GF, Stoeckli SJ (2018) Laryngoscope Investig Otolaryngol. Aug 9;3(4):283-289.
  10. Maximum Standardized Uptake Value (SUVmax) of Primary Tumor Predicts Occult Neck Metastasis in Oral Cancer. Morand GB, Vital DG, Kudura K, Werner J, Stoeckli SJ, Huber GF, Huellner MW (2018)
    Sci Rep. Aug 7;8(1):11817
  11. The expression of the cancer testis antigen MAGE A4: A favorable prognostic biomarker in salivary gland carcinomas related to low tumor grading. Vital D, Ikenberg K, Moch H, Roessle M, Huber GF (2018) Laryngoscope Investig Otolaryngol. Apr 19;3(3):182-190.
  12. Contrast-enhanced 18F-FDG-PET/CT for Differentiating Tumor and Radionecrosis in Head and Neck Cancer: Our experience in 37 Patients. Meerwein CM, Nakadate M, Stolzmann P, Vital D, Morand GB, Zweifel DF, Huber GF, Huellner MW (2018) Clin Otolaryngol. Jul 5
  13. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy. Finazzi T, Rordorf T, Ikenberg K, Huber GF, Guckenberger M, Garcia Schueler HI (2018), BMC Cancer. 2018 Apr 6;18(1):395
  14. [18F]Fluorocholine Uptake of Parathyroid Adenoma Is Correlated with Parathyroid Hormone Level. Alharbi AA, Alshehri FM, Albatly AA, Sah BR, Schmid C, Huber GF, Huellner MW (2018), Mol Imaging Biol. Mar 5 [Epub ahead of print], PD-L1 is a positive prognostic factor in squamous cell carcinoma of the nasal vestibule. Vital D, Holzmann D, Huber GF, Moch H, Morand GB, Ikenberg K (2018) Rhinology. Feb 21 [Epub ahead of print]
  15. Benefit of 18F-fluorocholine PET imaging in parathyroid surgery. Huber GF, Hüllner M, Schmid C, Brunner A, Sah B, Vetter D, Kaufmann PA, von Schulthess GK (2018), Eur Radiol. Jan 25 [Epub ahead of print]
  16. Outcome by treatment modality in sinonasal undifferentiated carcinoma (SNUC): A case-series, systematic review and meta-analysis. Morand GB, Anderegg N, Vital D, Ikenberg K, Huber GF, Soyka MB, Egger M, Holzmann D (2017), Oral Oncol. Dec;75:28-34
  17. Impact of human papillomavirus on outcome in patients with oropharyngeal cancer treated with primary surgery. Broglie MA, Stoeckli SJ, Sauter R, Pasche P, Reinhard A, de Leval L, Huber GF, Pezier TF, Soltermann A, Giger R, Arnold A, Dettmer M, Arnoux A, Müller M, Spreitzer S, Lang F, Lutchmaya M, Stauffer E, Espeli V, Martucci F, Bongiovanni M, Foerbs D, Jochum W (2017) Head Neck. Oct;39(10):2004-2015
  18. Early Timing of Thyroidectomy for Hyperthyroidism in Graves› Disease Improves Biochemical Recovery. Vital D, Morand GB, Meerwein C, Laske RD, Steinert HC, Schmid C, Brown ML, Huber GF (2017) World J Surg. 2017 Oct;41(10):2545-2550
  19. The presence of aberrant p53 pattern is a negative prognostic predictor in squamous cell carcinoma of the nasal vestibule. Vital D, Huber GF, Holzmann D, Moch H, Ikenberg K (2017), Eur Arch Otorhinolaryngol. Sep;274(9):3503-3512
  20. Local resectability assessment of head and neck cancer: Positron emission tomography/MRI versus positron emission tomography/CT. Sekine T, Barbosa FG, Delso G, Burger IA, Stolzmann P, Ter Voert EE, Huber GF, Kollias SS, von Schulthess GK, Veit-Haibach P, Huellner MW (2017), Head Neck. Aug; 39(8):1550-1558
  21. p16INK4a : A surrogate marker of high-risk human papillomavirus infection in squamous cell carcinoma of the nasal vestibule. Vital D, Holzmann D, Huber GF, Soyka MB, Moch H, Zimmermann DR, Ikenberg K (2017) Head Neck. Jul;39(7):1392-1398
  22. PET+MR versus PET/CT in the initial staging of head and neck cancer, using a trimodality PET/CT+MR system. Sekine T, de Galiza Barbosa F, Kuhn FP, Burger IA, Stolzmann P, Huber GF, Kollias SS, von Schulthess GK, Veit-Haibach P, Huellner MW (2017), Clin Imaging. Mar – Apr;42:232-239
  23. gamma ray probe for sentinel node mapping in HNSCC. Meerwein CM, Sekine T, Veit-Haibach P, Bredell MG, Huber GF, Huellner MW (2017)
    Eur Arch Otorhinolaryngol. Mar;274(3):1633-1642
  24. Interleukin-33 Expression Indicates a Favorable Prognosis in Malignant Salivary Gland Tumors. Rossle M, Cathomas G, Bonapace L, Sachs M, Dehler S, Storz M, Huber G, Moch H, Junt T, Mertz KD. Int J Surg Pathol 2016; 24(5):394-400.
  25. Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue. Ernst J, Ikenberg K, Apel B, Schumann DM, Huber G, Studer G, Rordorf T, Riesterer O, Rössle M, Korol D, Bredell MG (2016), Oncotarget. Nov 15;7(46):76151-76158
  26. IMRT/VMAT for malignancies in the head-and-neck region: Outcome in patients aged 80. Brown ML, Glanzmann C, Huber G, Bredell M, Rordorf T, Studer G (2016), Strahlenther Onkol. Aug;192(8):526-536
  27. Extending the limits of reconstructive microsurgery in elderly patients. Klein HJ, Fuchs N, Mehra T, Schweizer R, Giesen T, Calcagni M, Huber GF, Giovanoli P, Plock JA (2016), J Plast Reconstr Aesthet Surg. Aug;69(8):1017-1023
  28. No benefit for regional control and survival by planned neck dissection in primary irradiated oropharyngeal cancer irrespective of p16 expression. Maquieira R, Haerle SK, Huber GF, Soltermann A, Haile SR, Stoeckli SJ, Broglie MA (2016), Eur Arch Otorhinolaryngol. Jul;273(7):1841-1848
  29. Sentinel Node in Oral Cancer: The Nuclear Medicine Aspects. A Survey from the Sentinel European Node Trial. Tartaglione G, Stoeckli SJ, de Bree R, Schilling C, Flach GB, Bakholdt V, Sorensen JA, Bilde A, von Buchwald C, Lawson G, Dequanter D, Villarreal PM, Forcelledo MF, Amezaga JA, Moreira A, Poli T, Grandi C, Vigili MG, O’Doherty M, Donner D, Bloemena E, Rahimi S, Gurney B, Haerle SK, Broglie MA, Huber GF, Krogdah AL, Sebbesen LR, Odell E, Junquera Gutierrez LM, Barbier L, Santamara-Zuazua J, Jacome M, Nollevaux MC, Bragantini E, Lothaire P, Silini EM, Sesenna E, Dolivet G, Mastronicola R, Leroux A, Sassoon I, Sloan P, Colletti PM, Rubello D, McGurk M (2016) Clin Nucl Med. Jul;41(7):534-42
  30. Detection of Helicobacter pylori in head and neck cancer patients: Results from a prospective comparative study combining serology, PCR, and rapid urease test. Morand GB, Fellmann J, Laske RD, Weisert JU, Soltermann A, Zbinden R, Probst R, Huber GF (2016), Head Neck. May;38(5):759-774
  31. Risk profile for osteoradionecrosis of the mandible in the IMRT era. Studer G, Bredell M, Studer S, Huber G, Glanzmann C (2016) Strahlenther Onkol. Jan;192(1):32-39
  32. Perineural Invasion in Squamous Cell Carcinoma of the Oral Cavity: Histology, Tumor Stage, and Outcome. Laske RD, Scholz I, Ikenberg K, Meerwein C, Vital DG, Studer G, Roessle M, Huber GF (2016) Laryngoscope Investigative Otolaryngology. Jan 14:1(1):13-18
  33. Combined PET/CT-perfusion in patients with head and neck cancers might predict failure after radio-chemotherapy: a proof of concept study. Pietsch C, de Galiza Barbosa F, Hüllner MW, Schmid DT, Haerle SK, Huber GF, Studer G, Hany TF, Veit-Haibach P (2015), BMC Med Imaging. Dec 29;15(1):60
  34. Use of inpatient rehabilitation for cancer patients in Switzerland: who undergoes cancer rehabilitation? Ture M, Barth J, Angst F, Aeschlimann A, Schnyder U, Zerkiebel N, Perseus J, Renner C, Imesch P, Fuchs B, Huber GF, Walt H, Martin-Soelch C, Jenewein J (2015), Swiss Med Wkly. 2015 Dec 4;145
  35. Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer. Schilling C, Stoeckli SJ, Haerle SK, Broglie MA, Huber GF, Sorensen JA, Bakholdt V, Krogdahl A, von Buchwald C, Bilde A, Sebbesen LR, Odell E, Gurney B, O’Doherty M, de Bree R, Bloemena E, Flach GB, Villarreal PM, Fresno Forcelledo MF, Junquera Gutiérrez LM, Amézaga
    JA, Barbier L, Santamaría-Zuazua J, Moreira A, Jacome M, Vigili MG, Rahimi S, Tartaglione G, Lawson G, Nollevaux MC, Grandi C, Donner D, Bragantini E, Dequanter D, Lothaire P, Poli T, Silini EM, Sesenna E, Dolivet G, Mastronicola R, Leroux A, Sassoon I, Sloan P, McGurk M. (2015), Eur J Cancer. Dec;51(18):2777-2784
  36. Does airway intervention before primary nonsurgical therapy for T3/T4 laryngeal squamous cell carcinoma impact on oncological or functional outcomes? Schariatzadeh R, Pezier T, Studer G, Schmid S, Huber G (2015), Swiss Med Wkly. Nov 23;145
  37. Histopathological mapping of metastatic tumor cells in sentinel lymph nodes of oral and oropharyngeal squamous cell carcinomas. Denoth S, Broglie MA, Haerle SK, Huber GF, Haile SR, Soltermann A, Jochum W, Stoeckli SJ (2015)
    Head Neck. Oct;37(10):1477-1482
  38. Tumor stage, tumor site and HPV dependent correlation of perfusion CT parameters and [18F]-FDG uptake in head and neck squamous cell carcinoma. Nesteruk M, Lang S, Veit-Haibach P, Studer G, Stieb S, Glatz S, Hemmatazad H, Ikenberg K, Huber G, Pruschy M, Guckenberger M, Klöck S, Riesterer O (2015), Radiother Oncol. Oct;117(1):125-31
  39. 39. The value of 18 F-FDG-PET/CT imaging in oral cavity cancer patients following surgical reconstruction. Müller J, Hüllner M, Strobel K, Huber GF, Burger IA, Haerle SK (2015), Laryngoscope. Aug;125(8):1861-8
  40. Human papilloma virus and survival of oropharyngeal cancer patients treated with surgery and adjuvant radiotherapy. Broglie MA, Soltermann A, Haile SR, Huber GF, Stoeckli SJ (2015), Eur Arch Otorhinolaryngol. Jul; 272(7):1755-62
  41. Radiation induced lower cranial nerve palsy in patients with head and neck carcinoma. Janssen S, Glanzmann C, Yousefi B, Loewenich K, Huber G, Schmid S, Studer G (2015), Mol Clin Oncol. Jul;3(4):811-816
  42. Sensitivity and Specificity of Dual-Isotope 99mTc-Tetrofosmin and 123I Sodium Iodide Single Photon Emission Computed Tomography (SPECT) in Hyperparathyroidism. Sommerauer M, Graf C, Schäfer N, Huber G, Schneider P, Wüthrich R, Schmid C, Steinert H (2015), PLoS One. Jun 16;10(6)
  43. Unknown primary of the head and neck: A long-term follow-up. Lanzer M, Bachna-Rotter S, Graupp M, Bredell M, Rücker M, Huber G, Reinisch S, Schumann P (2015), J Craniomaxillofac Surg. May;43(4):574-9
  44. Less may be more: nodal treatment in neck positive head neck cancer patients. Studer G, Huber GF, Holz E, Glanzmann C (2015), Eur Arch Otorhinolaryngol. Jun;273(6):1549-56
  45. Post-treatment surveillance of head and neck cancer: pitfalls in the interpretation of FDG PETCT/MRI. Meerwein CM, Queiroz M, Kollias S, Hüllner M, Veit-Haibach P, Huber GF. (2015), Swiss Med Wkly. Feb 21;145
  46. Zenker’s diverticulum: outcome of endoscopic surgery is dependent on the intraoperative exposure. Murer K, Soyka MB, Broglie MA, Huber GF, Stoeckli SJ (2015), Eur Arch Otorhinolaryngol. Jan;272(1):167-73
  47. Outcome in squamous cell carcinoma of the nasal vestibule: a single center experience. Vital D, Morand G, Huber GF, Studer G, Holzmann D (2015)
    Head Neck. Jan;37(1):46-51
  48. Multilocular sinonasal malignant melanoma: a poor prognostic subgroup? Stanimirov Rossi O, Vital D, Soyka MB, Roth TN, Huber GF, Holzmann D (2015), Eur Arch Otorhinolaryngol. Jan;272(1):123-9
  49. Use of diffusion-weighted imaging (DWI) in PET/MRI for head and neck cancer evaluation. Queiroz MA, Hüllner M, Kuhn F, Huber GF, Meerwein C, Kollias S, von Schulthess G, VeitHaibach P (2014), Eur J Nucl Med Mol Imaging. Dec;41(12):2212-21
  50. Helicobacter pylori detected in pharyngeal and laryngeal pathologies in patients with proven gastric colonization. Fellmann J, Weisert JU, Soltermann A, Morand G, Morra L, Moch H, Huber GF, Probst R (2014), Head Neck. Nov;36(11):1562-6
  51. Success of salvage treatment: a critical appraisal of salvage rates for different subsites of HNSCC. Matoscevic K, Graf N, Pezier TF, Huber GF (2014), Otolaryngol Head Neck Surg. Sep;151(3):454-61
  52. Risk-adapted partial larynx and/or carotid artery sparing modulated radiation therapy of glottic cancer. Janssen S, Glanzmann C, Huber GF, Studer G (2014), Radiat Oncol. Jun 13;9:136
  53. PET/MRI and PET/CT in follow-up of head and neck cancer patients. Queiroz MA, Hüllner M, Kuhn F, Huber GF, Meerwein C, Kollias S, von Schulthess G, Veit-Haibach P (2014), Eur J Nucl Med Mol Imaging. Jun;41(6):1066-1075
  54. Individualized IMRT treatment approach for cervical lymph node metastases of unknown primary. Janssen S, Glanzmann C, Huber GF, Studer G (2014), Strahlenther Onkol. Apr;190(4):386-93
  55. Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed? Kuhn FP, Hüllner M, Mader CE, Kastrinidis N, Huber GF, von Schulthess GK, Kollias S, Veit-Haibach P (2014), J Nucl Med. Apr;55(4):551-8
  56. Airway management in head and neck cancer patients undergoing microvascular free tissue transfer: delayed extubation as an alternative to routine tracheotomy. Meerwein C, Pézier TF, Beck-Schimmer B, Schmid S, Huber GF (2014) Swiss Med Wkly. Mar 7;144
  57. Total thyroidectomy in patients with amiodarone-induced hyperthyroidism: when does the risk of conservative treatment exceed the risk of surgery? Meerwein C, Vital D, Greutmann M, Schmid C, Huber GF (2014) HNO. Feb;62(2):100-105
  58. Late term tolerance in head neck cancer patients irradiated in the IMRT era. Studer G, Linsenmeier C, Riesterer O, Najafi Y, Brown M, Yousefi B, Bredell M, Huber GF, Schmid S, Studer S, Zwahlen R, Rordorf T, Glanzmann C. (2013), Radiat Oncol. Nov 5;8:259
  59. ASPP2 suppresses squamous cell carcinoma via RelA/p65-mediated repression of p63. Tordella L, Koch S, Salter V, Pagotto A, Doondeea JB, Feller SM, Ratnayaka I, Zhong S, Goldin RD, Lozano G, McKeon FD, Tavassoli M, Fritsche F, Huber GF, Rössle M, Moch H, Lu X (2013) Proc Natl Acad Sci U S A. Oct 29;110(44):17969-74
  60. EGFR expression and copy number changes in low T-stage oral squamous cell carcinomas. Rössle M, Weber CS, Züllig L, Graf N, Jochum W, Stöckli SJ, Moch H, Huber GF. (2013), Histopathology. Aug;63(2):271-8
  61. High sex determining region Y-box 2 expression is a negative predictor of occult lymph node metastasis in early squamous cell carcinomas of the oral cavity. Züllig L, Roessle M, Weber C, Graf N, Haerle SK, Jochum W, Stoeckli SJ, Moch H, Huber GF. (2013), Eur J Cancer. May;49(8):1915-22
  62. 18F-FDG-PET/CT for the assessment of the contralateral neck in patients with head and neck squamous cell carcinoma. Kastrinidis N, Kuhn FP, Hany TF, Ahmad N, Huber GF, Haerle SK. (2013) Laryngoscope. May;123(5):1210-5
  63. Occult metastases detected by sentinel node biopsy in patients with early oral and oropharyngeal squamous cell carcinomas: impact on survival. Broglie MA, Haerle SK, Huber GF, Haile SR, Stoeckli SJ (2013), Head Neck. May;35(5):660-6
  64. Physiologic [18F]fluorodeoxyglucose uptake of floor of mouth muscles in PET/CT imaging: a problem of body position during FDG uptake? Haerle SK, Hany TF, Ahmad N, Burger I, Huber GF, Schmid DT (2013), Cancer Imaging. Feb 20;13:1-7
  65. Quality of life of oropharyngeal cancer patients with respect to treatment strategy and p16positivity. Broglie MA, Soltermann A, Haile SR, Röösli C, Huber GF, Schmid S, Stoeckli SJ (2013) Laryngoscope. Jan;123(1):164-70
  66. Combined PET/CT-perfusion in patients with head and neck cancers. Veit-Haibach P, Schmid D, Strobel K, Soyka JD, Schaefer NG, Haerle SK, Huber G, Studer G, Seifert B, Hany TF (2013), Eur Radiol. Jan;23(1):163-73
  67. Merkel cell carcinoma of the head and neck: a single institutional experience. Morand G, Vital D, Pézier T, Holzmann D, Roessle M, Cozzio A, Huber GF (2013), J Skin Cancer. ;2013:325086
  68. Validity of frozen section in sentinel lymph node biopsy for the staging in oral and oropharyngeal squamous cell carcinoma. Vorburger MS, Broglie MA, Soltermann A, Haerle SK, Haile SR, Huber GF, Stoeckli SJ (2012), J Surg Oncol. Dec;106(7):816-9
  69. Implications of a positive sentinel node in oral squamous cell carcinoma. Gurney BA, Schilling C, Putcha V, Alkureishi LW, Alvarez AJ, Bakholdt V, Barbier Herrero L, Barzan L, Bilde A, Bloemena E, Salces CC, Dalla Palma P, de Bree R, Dequanter D, Dolivet G, Donner D, Flach GB, Fresno M, Grandi C, Haerle S, Huber GF, Hunter K, Lawson G, Leroux A, Lothaire PH, Mamelle G, Silini EM, Mastronicola R, Odell EW, O’Doherty MJ, Poli T, Rahimi S, Ross GL, Zuazua JS, Santini S, Sebbesen L, Shoaib T, Sloan P, Sorensen JA, Soutar DS, Therkildsen MH, Vigili MG, Villarreal PM, von Buchwald C, Werner JA, Wiegand S, McGurk M (2012), Head Neck. Nov;34(11):1580-5
  70. Improved treatment outcomes with (18) F-FDG PET/CT for patients with advanced head and neck squamous cell carcinoma. Haerle SK, Soyka MB, Schmid DT, Ahmad N, Huber GF, Crook DW, Hany TF (2012), Head Neck. Sep;34(9):1205-1211
  71. Follow up after IMRT in oral cavity cancer: update. Studer G, Brown M, Bredell M, Graetz KW, Huber G, Linsenmeier C, Najafi Y, Riesterer O, Rordorf T, Schmid S, Glanzmann C (2012), Radiat Oncol. 2012 Jun 11;7:84

Übersichtsarbeiten (Reviews)

  1. Enhanced Recovery after Surgery in Head and Neck oncology. Huber GF, Dort JC (2018)
    Curr Opin Otolaryngol Head Neck Surg. Feb 9
  2. Optimal Perioperative Care in Major Head and Neck Cancer Surgery With Free Flap Reconstruction: A Consensus Review and Recommendations From the Enhanced Recovery After Surgery Society. Dort JC, Farwell DG, Findlay M, Huber GF, Kerr P, Shea-Budgell MA, Simon C, Uppington J, Zygun D, Ljungqvist O, Harris J (2017)
    JAMA Otolaryngol Head Neck Surg. Mar 1;143(3):292-30
  3. Modern management of Merkel cell carcinoma. Huber GF (2014)
    Curr Opin Otolaryngol Head Neck Surg. Apr;22(2):109-115
  4. Surgical oncologist or prophet? Huber G (2013)
    Praxis (Bern 1994). Jan 2;102(1):39-44 Review. German.

Fallbeschreibungen (case reports)

  1. High-grade Salivary Gland Adenocarcinoma Harboring ETV6-NTRK3 Fusion: Defined by Morphology or Molecular Aberration? Rupp NJ , Nemes C , Rushing EJ, Huber GF , Freiberger SN Head Neck Pathol 2021 Feb 5
  2. Recurrent unilateral peripheral facial palsy in a patient with an enlarged styloid process. Péus D, Kollias SS, Huber AM, Huber GF (2018 Head Neck. Dec 24. doi: 10.1002/hed.25384. [Epub ahead of print]
  3. A patient with a history of breast cancer and multiple bone lesions: a case report. Schnyder MA, Stolzmann P, Huber GF, Schmid C (2017)
    J Med Case Rep. May 6;11(1):127
  4. 4. Delayed diagnosis of sinonasal lymphoma due to bilateral manifestation. Kiessling SY, Soyka MB, Huber GF, Holzmann D, Laske RD (2017)
    Eur Arch Otorhinolaryngol. Feb;274(2):823-827
  5. Pneumo-thorax/mediastinum/(retro)peritoneum/ – a full house of complications following JET ventilation. Pézier TF, Widmer GM, Huber GF (2015)
    Acta Otorhinolaryngol Ital. Dec 29
  6. Ballistic Reconstruction of a Migrating Bullet in the Parapharyngeal Space. Bächinger D, Bolliger S, Huber GF, Laske RD (2015)
    Case Rep Otolaryngol 2015:245360
  7. Fatally invasive actinomycosis masquerading as a tonsillar carcinoma. Pézier TF, Kastrinidis N, Widmer GM, Huber GF, Probst R (2014)
    Head Neck. Dec;36(12):E129-30
  8. Cervical emphysema: an unusual presentation of laryngeal cancer. Pézier T, Schuknecht B, Schmid S, Huber GF (2014)
    J Laryngol Otol. Mar;128(3):299-301
  9. Secondary voice prosthesis insertion in patients without direct access to the upper esophagus. Meerwein C, Laske R, Castiglioni K, Bohlender JE, Huber GF (2014)
    Laryngoscope. Feb;124(2):469-71
  10. Epithelial cyst in the posterior triangle of the neck: atypical branchial cyst or cystic lymph node metastasis? Vital D, Huber GF, Pézier TF, Rössle M, Probst R, Widmer GM (2014)
    Case Rep Otolaryngol. 2014:912347
  11. Multifocal adult rhabdomyoma of the head and neck manifestation in 7 locations and review of the literature. de Trey LA, Schmid S, Huber GF (2013) Case Rep Otolaryngol. 2013;2013:758416


  1. Hämatologie und Onkologie, Fallorientierte Darstellung – rationale Diagnostik und Therapie Kreuzer KA, Beyer J (2016), pp 91-119, Georg Thieme Verlag, Stuttgart
  2. disekcija vrata Rancic Z (2015), pp 68-78, Niš University Press, Niš

Angeleitete Dissertationen

  1. Mettler Michael, Aug 2012, «Behandlungsresultate (Outcome) nach Behandlung von Larynx- und Pharynxkarzinomen im Zeitraum 1995-2007 am Kantonsspital Aarau»
  2. Züllig Lena, Mrz 2014, «High sex determining region Y-box 2 expression is a negative predictor of occult lymph node metastasis in early squamous cell carcinomas of the oral cavity»
  3. Weber Claudia, Jul 2014, «EGFR expression and copy number changes in low T-stage oral squamous cell carcinomas»
  4. Matoscevic Katja, Feb 2015, «Success of Salvage Treatment: A Critical Appraisal of Salvage Rates for Different Subsites of HNSCC».
  5. Amman Yanic, Jul 2021, «Impact of the new TNM-Staging System (8th edition) on oral tongue cancers.»


Aktive Teilnahme mit Vorträgen, Rundtischdiskussion und Liveoperation auf dem Gebiet der onkologischen Kopf-Halschirurgie, Schilddrüsenchirurgie, Laryngologie und Roboterchirurgie.



Domenica Ielapi, Lekha Pazhenkottil, Gyltene Salihu

Dr. Christine Huber-Musahl
T +41 (0)44 387 28 00
F +41 (0)44 387 28 02


  • European Head & Neck Society (member)
  • Swiss Head & Neck Society (president)
  • Verband Schweizer Ärzte / Foederatio Medicorum Helveticorum (FMH)
  • Zürcher Ärztegesellschaft 
  • Ordentliches Mitglied Schweizerische Gesellschaft für ORL (SGORL)
  • Arbeitsgruppe Kopf-Hals-Chirurgie (Vorsitz)
  • Prüfungskommission ORL (designierter Vorsitz)
  • Zürcher ORL-Gesellschaft
  • Ostschweizer ORL Gesellschaft (OSGORL)